MetaCap

Crescent Biopharma (CBIO) vs Zevra Therapeutics (ZVRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zevra Therapeutics (ZVRA) has outperformed Crescent Biopharma (CBIO) over the past year, gaining 1.9% versus a loss of 0.5%. Over five years, ZVRA leads with a +8.8% price change compared with -92.7% for CBIO. Crescent Biopharma is the larger company by market cap ($543.2 million vs $521.3 million), about 1.0 times the size.

Zevra Therapeutics converts more of its revenue into profit, with a net margin of 78.2% versus -1419.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CBIO-0.46%ZVRA+1.86%
+113%+38%-38%
Nov 21, 20251 yearNov 20, 2026
CBIO-93.09%ZVRA+4.29%
+94%-5%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CBIO versus ZVRA key metrics
MetricCBIOZVRA
Share price$13.00$8.76
Market cap$543.21M$521.26M
1-day change+0.70%-3.42%
YTD return+9.61%-2.23%
1-year return-0.46%+1.86%
5-year return-92.74%+8.82%
P/E ratio (TTM)—7.18
Forward P/E—9.84
EPS (TTM)$-7.29$1.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.84M$106.47M
Revenue growth (YoY)—+350.91%
Net income (latest FY)$-153.94M$83.23M
Gross margin—84.52%
Operating margin-1407.52%-59.12%
Net margin-1419.61%78.17%
52-week high$27.41$15.04
52-week low$8.72$8.01
Distance from 52-week high-52.57%-41.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+148.69%+162.56%
Average volume361.17K954.53K
Shares outstanding38.90M59.50M
Employees8061
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Zevra Therapeutics is more profitable, keeping 78.2 cents of every revenue dollar as net income versus -1419.6 cents for Crescent Biopharma.

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

About Zevra Therapeutics

ZVRA stock →

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 61 employees

CBIO vs ZVRA FAQ

Which is bigger, Crescent Biopharma or Zevra Therapeutics?

Crescent Biopharma (CBIO) is larger, with a market capitalization of $543.21M compared with $521.26M for Zevra Therapeutics (ZVRA).

Which stock has performed better over the past year, CBIO or ZVRA?

ZVRA returned +1.86% over the past 12 months, compared with -0.46% for CBIO (price return, excluding dividends). Past performance does not predict future results.

Are Crescent Biopharma and Zevra Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons